Medtech fundings for July 2016 stand at $612 million, led by the $183 million IPO of Bioventus, followed by the $49 million Series C funding of VytronUS, the $32 million funding of Endotronix and the $30 million funding of Senseonics.
Below are the top fundings for the month thus far. Check back before month end to see updates.
For a complete list of fundings in July 2016, see link.
Medtech fundings for June 2016 stand at $607 million, led by the $172.5 million post-IPO sale of Nevro’s convertible notes, the $75 million IPO (to happen in June) of OrthoPediatrics, and the $50 million funding of Clearside Biomedical.
Below are fundings for the month, thus far. Please revisit this post (and refresh your browser) for updates by month-end.
Type 1 diabetes gradually becomes less burdensome, with fewer complications, and improved quality of life for patients.
Type 2 diabetes continues to plague Western markets in particular, despite advances in diagnosis, treatment, and monitoring due to challenges in patient compliance.
Cancer five year survival rates will dramatically increase for many cancers. The number of hits on Google searches for “cure AND cancer” will reflect this.
Multifaceted approaches available for treatment of traumatic brain injury and spinal cord injury – encompassing exoskeletons to help retrain/rehabilitate and increase functional mobility, nerve grafting, cell/tissue therapy, and others.
Organ/device hybrids will proliferate and become viable alternatives to transplant, or bridge-to-transplant, for pulmonary assist, kidney, liver, heart, pancreas and other organ.
Stem cells have had dramatic success, and the science will have improved, but challenges remain, especially since the excitement around stem and other pluripotent cells has created a climate not far removed from the wild west – the potential of such open territory being up for grabs has drawn hordes of activity, not all in the best interests of patients or shareholders. But in this time frame, specific treatments will likely have become standards of care for some diseases, while the challenge and opportunity remain for many others.
From “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022”.
Cardiovascular Surgical and Interventional Procedures
Coronary Artery Bypass Graft Surgery
Coronary Mechanical and Laser Atherectomy
Coronary Angioplasty and Stenting
Ventricular Assist Device Placement
Total Artificial Heart
Donor Heart Transplantation
Lower Extremity Arterial Bypass Surgery
Percutaneous Transluminal Angioplasty (PTA) and Bare Metal Stenting
PTA and Drug-Eluting Stenting
PTA with Drug-Eluting Balloons
Mechanical and Laser Atherectomy
Catheter-Directed Thrombolysis and Thrombectomy
Surgical and Endovascular Thoracic Aortic Aneurysm Repair
Surgical and Endovascular Abdominal Aortic Aneurysm Repair
Vena Cava Filter Placement
Carotid Artery Stenting
Cerebral Aneurysm and Arteriovenous Malformation (AVM) repair
Fundings in medical technology for December 2015 stand at $360.4 million, led by Spectranetics’ $110 million debt funding, followed by the $44 million launch funding of Kallyope, the $40 million funding of NxThera, and the $38.5 million funding of Axonics Modulation Technologies.
Below are the top fundings for the month, thus far. Please revisit this post (and refresh your browser) during December to see new medtech fundings.
Medical technology fundings for October 2012 totaled just over $600 million, comprised of many fundings, but with the biggest ones being:
$76.2 million for LifeTech Scientific Corp. (minimally invasive interventional devices for cardiovascular and peripheral vascular applications)
$60.2 million for Vital Therapies, Inc. (bioartificial liver device)
$45 million for EnteroMedics, Inc. (devices to treat obesity, metabolic disease and other GI disorders)
$45 million for Fibrocell Sciences, Inc. (autologous cell therapies for use in aesthetic dermatology)
$40 million for Alimera Sciences, Inc. (intravitreal implant for the treatment of chronic diabetic macular edema)
$35 million for Tornier NV (joint replacement and related orthopedic implants)
$31 million for InSightec Immage Guided Treatment Ltd (non-invasive MRI-guided ultrasound surgical devices)
The overall trend in medtech fundings has been a slow recovery from 2008. Indeed, recent press from venture capital associations and others have argued that fundings are at upwards of an eight year low. The problem, however, with these reports is that they often look at medtech too narrowly (e.g., medical devices as opposed to medical devices, biomaterials and other products that are either complementary to or directly competitive with medical devices) or fail to account for fundings that come from both public and private investment, fundings from startup competitions, fundings from outside the U.S. Below is the actual trend, from 2009 though October 2012, based on individual financing we have tracked, month by month, since 2009 (you can see the individual fundings listed through June 2012 and the fundings separately for July, August, September and now October 2012).
Source: Compiled by MedMarket Diligence, LLC
Another way we have presented this data is to simply show the month-by-month financings with the seasonality (above) removed and a calculated trendline added. See below.
Source: Compiled by MedMarket Diligence, LLC
The data is hard and documented on these fundings, so the trendline above is not only reliable, but encouraging.